Cargando…

Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH

Dysfunctional mitochondrial function is believed to play a vital role in the progression of nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis. However, most evidence arises from animal models while there is limited data in humans. The characteristic histological finding of NASH...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalavalapalli, Srilaxmi, Barb, Diana, Leiva, Eddison Godinez, Lomonaco, Romina M, Fanous, Nada, Chug, Radhika, Friedman, Jeffrey, Rabe, Matthew, Cowan, Tyler M, Dillard, Rachel, Poulton, Danielle, Mansour, Lydia, Shrestha, Sulav, Cusi, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089219/
http://dx.doi.org/10.1210/jendso/bvab048.053
_version_ 1783686995481985024
author Kalavalapalli, Srilaxmi
Barb, Diana
Leiva, Eddison Godinez
Lomonaco, Romina M
Fanous, Nada
Chug, Radhika
Friedman, Jeffrey
Rabe, Matthew
Cowan, Tyler M
Dillard, Rachel
Poulton, Danielle
Mansour, Lydia
Shrestha, Sulav
Cusi, Kenneth
author_facet Kalavalapalli, Srilaxmi
Barb, Diana
Leiva, Eddison Godinez
Lomonaco, Romina M
Fanous, Nada
Chug, Radhika
Friedman, Jeffrey
Rabe, Matthew
Cowan, Tyler M
Dillard, Rachel
Poulton, Danielle
Mansour, Lydia
Shrestha, Sulav
Cusi, Kenneth
author_sort Kalavalapalli, Srilaxmi
collection PubMed
description Dysfunctional mitochondrial function is believed to play a vital role in the progression of nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis. However, most evidence arises from animal models while there is limited data in humans. The characteristic histological finding of NASH is hepatocellular injury with ballooning and inflammation, often associated with fibrosis in advanced disease. The aim of this study was to assess the role of mitochondrial function (eg, oxidative phosphorylation [OXPHOS] in patients with vs. without NASH and fibrosis. To this end, we recruited 38 patients with NAFLD with risk factors (obesity and/or type 2 diabetes) for NASH (age: 52±12 years; 37% male; BMI: 39.6±8.5 kg/m(2); HbA1c: 6.8±1.4%) in whom we assessed mitochondrial respiration and also performed measurements of insulin resistance (IR). Tissue was obtained by either a Tru-cut percutaneous liver biopsy (n=26) or a wedge biopsy during bariatric surgery (n=12). After tissue was separated for histological diagnosis, small liver samples (2–4 mg) were processed to quantify OXPHOS by measuring the mitochondrial oxygen consumption rate in individual complexes of mitochondria, expressed as pmol×mg wet weight(-1)×s(-1), using high-resolution respirometry, Oxygraph-2k. Based on liver histology, patients with NASH (n=18) compared to without NASH (n=20), had worse hyperinsulinemia and HOMA-IR (25.2±10.5 vs 14.9± 6.7 µU/ml and 8.9±4.3 vs. 4.9±2.9 mg/dl × µU/ml, respectively) and higher OXPHOS (all p<0.05), although well matched for age, BMI, HbA1c and % with diabetes. This was likely an adaptation to IR and higher FFA flux to the liver. We then examined patients based specifically on disease activity, using a combined score of hepatocyte ballooning and inflammation (necroinflammation score [NIS]) and divided as mild (n=16), moderate (n=14) or severe (n=8) NIS (also well matched for relevant clinical parameters). Patients in the moderate vs. mild NIS group disease activity had increased mitochondrial respiration as represented by OXPHOS (45.9±11.8 vs. 31.3±9.8), electron transport chain activity (ETC) (61.0±17.6 vs. 46.4±15.2) and state 3 respiration induced by ADP (20.7±4.9 vs. 16.4±4.6 pmol×mg wet weight(-1)×s(-1); all p<0.05). There was a trend for these parameters to decline in patients with severe vs. moderate disease activity, that was further accentuated when patients with NASH also had clinically significant fibrosis compared to those with mild or no fibrosis (OXPHOS: 37.9±7.8 vs. 49.8±12.5, p=0.04; and ETC: 49.8±13.4 vs. 67.5±16.1, p=0.02). Conclusion: In patients with NASH, there is an early hepatic mitochondrial adaptation to account for the state of more severe insulin resistance in steatohepatitis compared to simple steatosis. This adaptation is impaired when disease activity worsens and is most evident once patients develop steatohepatitis with significant fibrosis.
format Online
Article
Text
id pubmed-8089219
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80892192021-05-06 Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH Kalavalapalli, Srilaxmi Barb, Diana Leiva, Eddison Godinez Lomonaco, Romina M Fanous, Nada Chug, Radhika Friedman, Jeffrey Rabe, Matthew Cowan, Tyler M Dillard, Rachel Poulton, Danielle Mansour, Lydia Shrestha, Sulav Cusi, Kenneth J Endocr Soc Adipose Tissue, Appetite, and Obesity Dysfunctional mitochondrial function is believed to play a vital role in the progression of nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis. However, most evidence arises from animal models while there is limited data in humans. The characteristic histological finding of NASH is hepatocellular injury with ballooning and inflammation, often associated with fibrosis in advanced disease. The aim of this study was to assess the role of mitochondrial function (eg, oxidative phosphorylation [OXPHOS] in patients with vs. without NASH and fibrosis. To this end, we recruited 38 patients with NAFLD with risk factors (obesity and/or type 2 diabetes) for NASH (age: 52±12 years; 37% male; BMI: 39.6±8.5 kg/m(2); HbA1c: 6.8±1.4%) in whom we assessed mitochondrial respiration and also performed measurements of insulin resistance (IR). Tissue was obtained by either a Tru-cut percutaneous liver biopsy (n=26) or a wedge biopsy during bariatric surgery (n=12). After tissue was separated for histological diagnosis, small liver samples (2–4 mg) were processed to quantify OXPHOS by measuring the mitochondrial oxygen consumption rate in individual complexes of mitochondria, expressed as pmol×mg wet weight(-1)×s(-1), using high-resolution respirometry, Oxygraph-2k. Based on liver histology, patients with NASH (n=18) compared to without NASH (n=20), had worse hyperinsulinemia and HOMA-IR (25.2±10.5 vs 14.9± 6.7 µU/ml and 8.9±4.3 vs. 4.9±2.9 mg/dl × µU/ml, respectively) and higher OXPHOS (all p<0.05), although well matched for age, BMI, HbA1c and % with diabetes. This was likely an adaptation to IR and higher FFA flux to the liver. We then examined patients based specifically on disease activity, using a combined score of hepatocyte ballooning and inflammation (necroinflammation score [NIS]) and divided as mild (n=16), moderate (n=14) or severe (n=8) NIS (also well matched for relevant clinical parameters). Patients in the moderate vs. mild NIS group disease activity had increased mitochondrial respiration as represented by OXPHOS (45.9±11.8 vs. 31.3±9.8), electron transport chain activity (ETC) (61.0±17.6 vs. 46.4±15.2) and state 3 respiration induced by ADP (20.7±4.9 vs. 16.4±4.6 pmol×mg wet weight(-1)×s(-1); all p<0.05). There was a trend for these parameters to decline in patients with severe vs. moderate disease activity, that was further accentuated when patients with NASH also had clinically significant fibrosis compared to those with mild or no fibrosis (OXPHOS: 37.9±7.8 vs. 49.8±12.5, p=0.04; and ETC: 49.8±13.4 vs. 67.5±16.1, p=0.02). Conclusion: In patients with NASH, there is an early hepatic mitochondrial adaptation to account for the state of more severe insulin resistance in steatohepatitis compared to simple steatosis. This adaptation is impaired when disease activity worsens and is most evident once patients develop steatohepatitis with significant fibrosis. Oxford University Press 2021-05-03 /pmc/articles/PMC8089219/ http://dx.doi.org/10.1210/jendso/bvab048.053 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adipose Tissue, Appetite, and Obesity
Kalavalapalli, Srilaxmi
Barb, Diana
Leiva, Eddison Godinez
Lomonaco, Romina M
Fanous, Nada
Chug, Radhika
Friedman, Jeffrey
Rabe, Matthew
Cowan, Tyler M
Dillard, Rachel
Poulton, Danielle
Mansour, Lydia
Shrestha, Sulav
Cusi, Kenneth
Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title_full Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title_fullStr Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title_full_unstemmed Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title_short Severe Disease Activity and Liver Fibrosis Are Associated With a Lack of Hepatic Mitochondrial Adaptation in Patients With NASH
title_sort severe disease activity and liver fibrosis are associated with a lack of hepatic mitochondrial adaptation in patients with nash
topic Adipose Tissue, Appetite, and Obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089219/
http://dx.doi.org/10.1210/jendso/bvab048.053
work_keys_str_mv AT kalavalapallisrilaxmi severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT barbdiana severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT leivaeddisongodinez severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT lomonacorominam severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT fanousnada severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT chugradhika severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT friedmanjeffrey severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT rabematthew severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT cowantylerm severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT dillardrachel severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT poultondanielle severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT mansourlydia severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT shresthasulav severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash
AT cusikenneth severediseaseactivityandliverfibrosisareassociatedwithalackofhepaticmitochondrialadaptationinpatientswithnash